⁶⁸Ga-DOTATATE PET Requisition to PET Centre TO BE COMPLETED BY THE REFERRING PHYSICIAN

The following indications are part of the Ontario PET Registry. Completion of a post scan form is required following the PET scan. Together the pre and post scan information will provide vital data to build evidence for use of PET for this indication. Please accurately complete both the pre and post scan forms.

Referring Staff Physician Name:
Staff Physician Phone: () ext. Fax: () CPSO No:
Staff Physician email:
Patient Name:
OHIP Number:
Telephone: () Postal Code:
Date of birth: // // Gender: M F Other
<u>IMPORTANT NOTE FOR PATIENTS TREATED WITH SOMATOSTATIN:</u> It is recommended that PET be scheduled just prior (e.g. 0-7 days) to the monthly dose of long acting octreotide or if patients are switched to short acting somatostatin, the dose be deferred until after the scan.
Complete sections A, B, C & D
<u>Section A</u> – NET Demographics
NET Grade: Grade I Grade 2 Grade 3 Unknown
Ki-67 score: Low (<6%) Intermediate (6-10%) High (>10%); specify: Unknown
Differentiation: Doorly Differentiated Moderately Differentiated Well Differentiated Unknown
Site of Primary (or suspected Primary) Disease: Small Bowel Pancreas Lung Other (specify):
Metastases: Suspected Confirmed N/A
Operability: Operable Non-Operable Unknown
Classification: Functional Non-Functional Unknown
<u>Section B</u> – Prior Octreotide Scan
Octreotide Scan Performed: Yes, date of scan: //// MM / DD NO (continue to Section C)
Overall Octreotide Scan Results: Positive Negative Equivocal
If overall Octreotide scan results are positive/equivocal, complete the following questions:
 Primary Tumor/ Local recurrence: Yes No Equivocal
 Nodal Metastases: Yes No Equivocal
 Distant Metastases: Yes No Equivocal

Version Date: November 1, 2019

Page 1 of 2

*PET Centre Use Only: PET Access Program - PET Centre must fax these requests to PET Scans Ontario for review (416) 217-1327

⁶⁸Ga-DOTATATE PET Requisition to PET Centre TO BE COMPLETED BY THE REFERRING PHYSICIAN

Complete sections A, B, C & D

Patient Name:

Section C – Choose ONLY ONE Indication
DIAGNOSIS (NET) – PET for identification of primary tumour when there is clinical suspicion of Neuroendocrine Tumour (NET), and primary tumour site is unknown or uncertain. Patients should have no definitive evidence of disease on CT & elevated biochemical markers (e.g., 5-HIAA ± elevated Chromogranin A)
INITIAL STAGING (NET) – PET for the staging of patients upon initial diagnosis of Neuroendocrine Tumour.
RE-STAGING (NET) – PET for the re-staging of patients with Neuroendocrine Tumour (NET). When surgery (e.g., de-bulking, focal ablation, liver directed therapy) or PRRT is being considered; OR Where conventional imaging is negative or equivocal at time of clinical and/or biochemical progression
Indicate if patient had prior ⁶⁸ Ga-DOTATATE PET:
*OTHER (requires case-by-case review through the PET Access Program) – PET as a problem-solving tool in patients with Neuroendocrine Tumour (NET) when confirmation of site of disease and/or disease extent may impact clinical management.
Section D – If PET were NOT available, what is your Current Management Plan (choose from i, ii, and iii)
Choose the most appropriate treatment option(s) according to the current CT/MR staging data.
i) Treatment Intent: Curative Palliative Observation
ii) Treatment Options (select all that apply): Surgery: Curative De-bulking Liver Directed Therapy: Embolization Other, (specify):
Somatostatin Analogues
Other Systemic Therapy, (specify type): Chemotherapy (specify):
Targeted Agents (specify):
Other (specify):
Peptide Receptor Radiotherapy Other (specify):
 iii) Was this treatment plan presented at a Multi-disciplinary Cancer conference (MCC): Yes No If no, will this treatment plan be presented at an upcoming MCC: Yes No
The following documents should be attached to this requisition: Relevant Imaging Studies within the previous 3 months (i.e. CT, US, MR, Other) (Provide Digital Images to the patient to take with them to the PET Centre, to enable direct comparison to PET) Consult Note or Referral Letter (outlining the relevant clinical history) Pathology Report
Physician Signature: Date:
Fax Instructions

Fax the completed request form, (pages 1 and 2), along with the required supporting documentation to: • Toronto – Princess Margaret Cancer Centre (416) 946-2144

*PET Centre Use Only: PET Access Program - PET Centre must fax these requests to PET Scans Ontario for review (416) 217-1327